Collegium Pharmaceutical Stock Options Expiring on 17th of May

COLL Stock  USD 31.36  0.35  1.10%   

Collegium Pharmaceutical Selling And Marketing Expenses Over Time

   Selling And Marketing Expenses   
       Timeline  

Collegium Pharmaceutical Market Cap Over Time

   Market Cap   
       Timeline  

Collegium Total Stockholder Equity

Total Stockholder Equity

127.56 Million

At this time, Collegium Pharmaceutical's Total Stockholder Equity is quite stable compared to the past year.

Collegium Pharmaceutical Corporate Management

MD FAAFPExecutive OfficerProfile
Bart DunnExecutive DevelopmentProfile
Scott SudduthHead OperationsProfile
Christopher MDVice RelationsProfile
RPh PharmCoFounder ChairmanProfile
Marlo ManningHead HRProfile

Additional Information and Resources on Investing in Collegium Stock

When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
51.976
Earnings Share
2.51
Revenue Per Share
17.054
Quarterly Revenue Growth
0.001
Return On Assets
0.1056
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.